Scientists reveal that new combination of clinically tested drugs inhibits growth of lung tumors

Lung cancer: Scientists find answer to resistance
The research team of Professor Henrik Ditzel, University of Southern Denmark, has revealed that a new combination of clinically tested drugs inhibits the growth of tumors in lung cancer, thereby potentially improving patients' survival. Credit: University of Southern Denmark

Research at the University of Southern Denmark has revealed that a new combination of clinically tested drugs inhibits the growth of tumours, thereby potentially improving patients' survival.

Scientists at the University of Southern Denmark have found a new strategy for overcoming the resistance, which many lung patients develop towards a recent drug, which can arrest the growth of tumours.

An EGFR tyrosine kinase inhibitor is a targeted drug that is used to block a special signal pathway (EGFR) in the cancer cells, thereby arresting . However, often the positive effect does not last. After about a year, the have found other ways to multiply, so many patients become resistant to the .

"We investigated how the cancer cells evade the treatment. They do this in at least 10 different ways, and there is no denying that it complicates the challenge of finding a subsequent treatment that, in the longer term, can stop tumour growth and improve survival of lung cancer patients," says Professor and Consultant Henrik Ditzel from the Department of Molecular Medicine at the University of Southern Denmark and the Department of Oncology at Odense University Hospital.

Common factors for resistance

His research group can now prove that there is a common mechansim for the cells that develop resistance. The cells upgrade a different (AKT), resulting in elevated AKT activity in cell samples from lung cancer patients, who no longer respond to treatment with .

So scientists (in cell cultures and in mice) tested a combination treatment using an EGFR tyrosine kinase inhibitor and an AKT inhibitor, and the tests showed that the tumour growth was arrested.

According to Henrik Ditzel, it may not be very long before the results, which has just been published in the highly regarded journal, Nature Communications with PhD student Kirstine Jacobsen as first author, can change management of lung cancer patients.

"An approved drug already exists to inhibit AKT activities. So we are aiming very soon at embarking on a clinical study, in which lung cancer patients, whose malignant tumour has increased AKT, will be given a combination treatment using the two known drugs at the same time. In the longer term, we hope that this will prolong the lives of , if we can combine several treatments - in other words, turning them into a single treatment - instead of administering different treatments in succession," says Henrik Ditzel.

  • Lung cancer is the leading cause of cancer mortality in the world. The study looks at non-small cell lung cancer, which accounts for virtually 80% of all cases of cancer.
  • The study was conducted in collaboration with scientists and doctors from Barcelona and San Francisco.

Explore further

Osimertinib improves symptoms in advanced lung cancer patients

More information: Kirstine Jacobsen et al, Convergent Akt activation drives acquired EGFR inhibitor resistance in lung cancer, Nature Communications (2017). DOI: 10.1038/s41467-017-00450-6
Journal information: Nature Communications

Citation: Scientists reveal that new combination of clinically tested drugs inhibits growth of lung tumors (2017, September 8) retrieved 21 May 2019 from https://medicalxpress.com/news/2017-09-scientists-reveal-combination-clinically-drugs.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.
0 shares

Feedback to editors

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more